OpenMFM · Maternal-Fetal Medicine

Sickle Cell SS Disease

in Pregnancy

First-Visit Workup: Initial Evaluation Framework

HbSS disease requires a structured baseline evaluation to distinguish disease-related complications from pregnancy-specific pathology and to prevent serious transfusion-related harm.

HbSS · First Trimester Booking Labs Multidisciplinary: MFM + Hematology + Obstetrics

Why the First Visit Matters Framework

Three goals of the booking evaluation
Establish Baselines Before complications arise

Hemoglobin, organ function, and proteinuria must be documented early — you cannot interpret late-pregnancy changes without them.

Prevent Transfusion Harm Alloimmunization risk is high

Extended red cell phenotyping before any transfusion is a patient-safety requirement, not an optional add-on.

Activate the Team Referrals at first contact

MFM, hematology, and the blood bank should be engaged at or before the first prenatal visit.

Hematology Baseline

First priority · Order at booking
  • CBC with differential — Baseline Hgb typically 6–9 g/dL in HbSS; establishes the patient's steady-state
  • Reticulocyte count — Quantifies steady-state hemolytic rate; essential for monitoring
  • LDH — Second hemolysis marker; also useful for tracking disease activity through pregnancy
  • Hemoglobinopathy Fractionation / HPLC — Quantifies HbS%; critical if patient was recently on hydroxyurea (must stop in pregnancy) or received transfusions
Key point: Hydroxyurea is generally contraindicated in pregnancy. Confirm discontinuation and transition to alternative management (prophylactic or on-demand transfusion) based on prior disease history.

Transfusion Safety & Alloimmunization Patient Safety

Critical — complete before any transfusion

SCD patients have a high risk of developing red cell alloantibodies, which can cause delayed hemolytic transfusion reactions (DHTR) or hemolytic disease of the fetus and newborn (HDFN).

Required testing:

  • ABO/Rh(D) typing — included in standard prenatal profile
  • Antibody screen — baseline; repeat if transfusion planned
  • Extended RBC phenotype: C/c, E/e, Kell — minimum required for safe transfusion matching
  • Antibody ID — if screen is positive or prior positive history exists
Rule: All blood for transfusion MUST be extended-match (at minimum C, E, and Kell) to reduce DHTR and HDFN risk. Obtain a comprehensive transfusion history from all prior institutions — historical antibodies may be below current detection limits.

Renal & Hepatic Baseline

End-organ assessment

Renal

  • Serum creatinine, BUN, electrolytes — sickle nephropathy may be subclinical
  • Urine protein/creatinine ratio (UPC) or 24-hour urine protein — mandatory baseline because chronic proteinuria from sickle nephropathy will otherwise make preeclampsia diagnosis impossible later

Hepatic

  • AST, ALT, alkaline phosphatase
  • Total and direct bilirubin — baseline for sickle hepatopathy and hepatic sequestration
Efficient option: CMP (Labcorp 322000) covers creatinine/eGFR, BUN, electrolytes, AST, ALT, alk phos, total bilirubin. Add direct bilirubin separately (001222).

Preeclampsia Risk & Prophylaxis Action Required

SCD is high-risk for preeclampsia
  • HbSS patients carry elevated risk for preeclampsia throughout pregnancy
  • Baseline proteinuria from sickle nephropathy creates diagnostic ambiguity — the baseline UPC is the only defense against this

Management:

  • Document baseline UPC at booking (Labcorp 003129)
  • Start low-dose aspirin (81–150 mg daily) at 12 weeks for preeclampsia prophylaxis — SCD qualifies as a high-risk indication
Without a documented baseline UPC, new-onset preeclampsia in a patient with chronic sickle nephropathy cannot be reliably diagnosed. This is a clinical safety issue.

Additional Assessments

Complete at first visit based on history

Iron Status

  • Ferritin + Iron/TIBC — assess for iron overload (frequently transfused patients) vs. iron deficiency (less common in HbSS)

Vitamin D

  • 25-OH Vitamin D — deficiency is prevalent in SCD and associated with poor outcomes; check and supplement routinely

Cardiac Evaluation (if indicated)

  • History of pulmonary hypertension or severe anemia → consider ECG and baseline echocardiogram (TTE)
  • Assess tricuspid regurgitant jet velocity (TRV) as a marker for pulmonary hypertension

Fetal Risk & Partner Testing

Genetic counseling at first visit
  • Partner hemoglobinopathy testing is essential if carrier status is unknown
    • HbS, HbC, or β-thalassemia trait in the partner creates risk for an affected fetus
    • Labcorp 121690 (Hemoglobinopathy Fractionation Cascade) for partner; 121363 adds α-thalassemia reflex when microcytosis is present

If partner is a carrier:

  • Offer invasive prenatal diagnosis (CVS or amniocentesis) or NIPT for fetal SCD
  • Fetal Sickle Cell Analysis (Labcorp 482091) — requires maternal specimen for maternal cell contamination analysis; not a routine screen
Genetic counseling should be offered to all couples where both partners are carriers of hemoglobinopathy traits regardless of fetal testing decision.

Critical Safety Alerts Do Not Miss

Three things that cannot wait
Stop Hydroxyurea Contraindicated in pregnancy

Confirm at first contact. Transition to transfusion-based management as clinically indicated. Document the conversation.

Extended Match Transfusions Every transfusion, every time

C, E, and Kell matching is mandatory. Obtain full transfusion history from all prior centers before any blood product is given.

Baseline Proteinuria Order before 14 weeks

Without a documented baseline UPC, diagnosing preeclampsia in a patient with sickle nephropathy is clinically unreliable.

Quick Order Set — Labcorp

First-trimester SCD booking · Verified Labcorp test numbers
# Test Labcorp Code
Prenatal booking panel (CBC, ABO/Rh, Ab screen, UA, infectious) Pregnancy Initial Screening Profile 144053
Hemolysis Reticulocyte Count 005280
Hemolysis LDH 001115
Hemoglobinopathy status Hemoglobinopathy Fractionation Cascade 121690
Extended phenotype RBC Antigen Typing C/c · E/e · K (Kell) 006010 / 006018 / 006068
Renal + hepatic Comprehensive Metabolic Panel 322000
Hepatic add-on Direct Bilirubin 001222
Preeclampsia baseline Urine Protein/Creatinine Ratio 003129
Iron status Ferritin · Iron/TIBC 004598 / 001321
Vitamin D 25-OH Vitamin D 081950
Add 482091 (Fetal SCD Analysis) only if fetal diagnostic testing is indicated after partner testing Verify all codes in Labcorp Link or your local EHR interface

Key Takeaways

What to do at the first visit
  • Book all baseline labs in the first trimester — CBC, retic, LDH, Hgb fractionation, extended RBC phenotype, CMP, direct bili, UPC, ferritin, iron, vitamin D, full prenatal panel
  • Confirm hydroxyurea is stopped; document and plan alternative management
  • Extended-match blood policy must be in place before any transfusion occurs
  • Low-dose aspirin at 12 weeks — SCD is a high-risk preeclampsia indication
  • Partner hemoglobinopathy testing — offer genetic counseling regardless of result
  • Multidisciplinary team: MFM + hematology + blood bank from visit one
Sources: EvidenceMD (2026-04-27) · AJOG · ASH Blood · BJH · Labcorp test directory

Source: EvidenceMD — Workup for Prenatal Sickle Cell SS Disease (2026-04-27) Render with: marp --html --theme-set ".\output\marp\OpenMFM\openmfm-patient.css" ".\output\marp\OpenMFM\Prenatal Sickle Cell SS Disease - Clinician Deck.md" -o ".\output\marp\OpenMFM\Prenatal Sickle Cell SS Disease - Clinician Deck.html"

← OpenMFM Library